Eagle Asset Management Inc. cut its holdings in Bruker Co. (NASDAQ:BRKR) by 17.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 403,134 shares of the medical research company’s stock after selling 83,375 shares during the quarter. Eagle Asset Management Inc.’s holdings in Bruker were worth $15,496,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Hanseatic Management Services Inc. grew its position in shares of Bruker by 52.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 579 shares during the last quarter. Captrust Financial Advisors grew its position in shares of Bruker by 164.7% in the fourth quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 1,135 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Bruker in the fourth quarter valued at approximately $176,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in shares of Bruker in the fourth quarter valued at approximately $192,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Bruker by 8.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,136 shares of the medical research company’s stock valued at $212,000 after purchasing an additional 550 shares during the last quarter. Institutional investors and hedge funds own 69.14% of the company’s stock.
Several analysts have recently commented on BRKR shares. BTIG Research reiterated a “buy” rating and issued a $44.00 price target (up from $42.00) on shares of Bruker in a research report on Tuesday, February 12th. Needham & Company LLC reiterated a “strong-buy” rating and issued a $46.00 price target (up from $39.00) on shares of Bruker in a research report on Monday. Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research report on Tuesday, January 29th. BidaskClub upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research report on Friday, January 11th. Finally, Deutsche Bank upgraded shares of Bruker from a “hold” rating to a “buy” rating and increased their price target for the company from $40.00 to $50.00 in a research report on Friday, April 12th. One analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Bruker currently has an average rating of “Buy” and an average price target of $43.71.
Shares of NASDAQ BRKR opened at $42.32 on Thursday. Bruker Co. has a 1 year low of $26.10 and a 1 year high of $44.47. The company has a market cap of $6.82 billion, a P/E ratio of 30.25, a PEG ratio of 2.37 and a beta of 1.44. The company has a current ratio of 2.18, a quick ratio of 1.33 and a debt-to-equity ratio of 0.36.
Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, May 2nd. The medical research company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.04. Bruker had a net margin of 9.53% and a return on equity of 26.93%. The firm had revenue of $461.40 million for the quarter, compared to analyst estimates of $450.46 million. During the same quarter last year, the business earned $0.24 earnings per share. Bruker’s revenue was up 6.9% compared to the same quarter last year. Sell-side analysts anticipate that Bruker Co. will post 1.59 earnings per share for the current year.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Read More: What is Net Asset Value (NAV)?
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.